AI Designs First Universal Coronavirus Vaccine Tested in Humans

AI Creates Broad-Spectrum Vaccine Component

Researchers at the University of Cambridge have completed early human trials of a vaccine whose core component was designed entirely by artificial intelligence—a first in vaccine development. The experimental vaccine targets the entire coronavirus family, including all COVID-19 variants and animal viruses that could trigger future pandemics.

The approach represents a departure from traditional vaccine design, which typically chases current viral strains. Instead, the Cambridge team fed genetic sequences from multiple coronaviruses into an AI system, which then engineered a "super-antigen" capable of training the immune system to recognize the entire virus family, even accounting for mutations and cross-species transmission.

Why It Matters

This technology could fundamentally change pandemic preparedness by creating vaccines before outbreaks occur rather than scrambling to develop them afterward. If successful at scale, AI-designed universal vaccines could eliminate the need for annual updates to flu shots and provide protection against emerging threats before they spread.

Early Safety Results and Next Steps

The initial safety trial involved 39 participants and showed the vaccine was well-tolerated, according to findings published in the Journal of Infection. While immune responses were described as "modest," a larger study with approximately 200 participants is now underway to better assess how effectively the vaccine trains the immune system.

Prof. Jonathan Heeney, who led the Cambridge research, explained the goal is to move from reactive to proactive vaccine development. "We're always behind," he said, describing current approaches. "What we're trying to do is get ahead of the curve."

Prof. Saul Faust from the University of Southampton, who conducted some of the trials, said the AI design "definitely has potential" and noted the technology excels at designing vaccines for rapidly changing viruses.

Expanding to Other Viral Threats

The Cambridge team is already applying this approach to other pathogens. Animal studies are underway for a universal seasonal flu vaccine that would not require yearly reformulation, plus an H5N1 bird flu vaccine to address the virus currently devastating bird populations. The researchers are also developing a vaccine for viral hemorrhagic fevers, including Ebola species—particularly relevant given the ongoing outbreak in the Democratic Republic of Congo caused by an Ebola strain lacking a dedicated vaccine.

Prof. Andy Pollard, director of the Oxford Vaccine Group, called the approach "fascinating" and said AI would be a "game changer" for vaccine research, potentially accelerating development and saving lives by predicting immune responses more accurately.

Prof. Marian Knight, scientific director for the National Institute for Health and Care Research, described the trial results as "a pivotal leap forward in our ability to deliver broad, lasting viral protection."

The research was first reported by BBC News.